Drug Profile
Research programme: cannabinoid therapeutics - CannaPharmaRx
Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator CannaPharmaRx
- Class Cannabinoids; Small molecules
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Eye disorders; Gastrointestinal disorders; Infections; Inflammation; Metabolic disorders; Neurodegenerative disorders; Pain
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for research development in Cancer in USA
- 28 Dec 2019 No recent reports of development identified for research development in Eye-disorders in USA
- 28 Dec 2019 No recent reports of development identified for research development in Gastrointestinal-disorders in USA